These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29055114)

  • 1. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks.
    Kanthaje S; Makol A; Chakraborti A
    Hepatol Res; 2018 Jan; 48(1):5-14. PubMed ID: 29055114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
    Shi Y; Huang A
    Tumour Biol; 2015 Nov; 36(11):8455-63. PubMed ID: 26026584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma.
    Hu X; Zhu H; Shen Y; Zhang X; He X; Xu X
    Front Oncol; 2021; 11():696705. PubMed ID: 34367979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
    Wei L; Wang X; Lv L; Liu J; Xing H; Song Y; Xie M; Lei T; Zhang N; Yang M
    Mol Cancer; 2019 Oct; 18(1):147. PubMed ID: 31651347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma.
    Lai Y; Feng B; Abudoureyimu M; Zhi Y; Zhou H; Wang T; Chu X; Chen P; Wang R
    Front Oncol; 2019; 9():1156. PubMed ID: 31750247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
    Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
    Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of microRNA in the resistance to treatment of hepatocellular carcinoma.
    Pratama MY; Pascut D; Massi MN; Tiribelli C
    Ann Transl Med; 2019 Oct; 7(20):577. PubMed ID: 31807558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
    Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
    Zhang PF; Wang F; Wu J; Wu Y; Huang W; Liu D; Huang XY; Zhang XM; Ke AW
    J Cell Physiol; 2019 Mar; 234(3):2788-2794. PubMed ID: 30132868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
    J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
    Vaira V; Roncalli M; Carnaghi C; Faversani A; Maggioni M; Augello C; Rimassa L; Pressiani T; Spagnuolo G; Di Tommaso L; Fagiuoli S; Rota Caremoli E; Barberis M; Labianca R; Santoro A; Bosari S
    Liver Int; 2015 Mar; 35(3):1077-86. PubMed ID: 25040368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions.
    Fornari F; Giovannini C; Piscaglia F; Gramantieri L
    J Hepatocell Carcinoma; 2021; 8():741-757. PubMed ID: 34239844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.
    Vasuri F; Visani M; Acquaviva G; Brand T; Fiorentino M; Pession A; Tallini G; D'Errico A; de Biase D
    World J Gastroenterol; 2018 Jul; 24(25):2647-2660. PubMed ID: 29991871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.